Linked Life Data

17233770

Source:http://linkedlifedata.com/resource/pubmed/id/17233770

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17233770rdf:typepubmed:Citationlld:pubmed
pubmed-article:17233770lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0332305lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0303611lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C1337333lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0034606lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0441633lld:lifeskim
pubmed-article:17233770lifeskim:mentionsumls-concept:C0332324lld:lifeskim
pubmed-article:17233770pubmed:issue5lld:pubmed
pubmed-article:17233770pubmed:dateCreated2007-2-22lld:pubmed
pubmed-article:17233770pubmed:abstractTextWe evaluated the additional benefit of Technetium(99)-sestamibi (99mTc-MIBI) scanning in comparison with standard X-ray techniques for multiple myeloma patients either at diagnosis or during follow-up. Between February 2001 and January 2005, 397 whole body scans were acquired. On 229 scans performed at diagnosis, 146 (64%) were positive and 81 cases have discordant X-ray results. The sensitivity of 99mTc-MIBI and X-ray were 77% and 45% respectively. As a result of 99mTc-MIBI, 40% of asymptomatic myeloma patients were up-staged. The positivity of 99mTc-MIBI correlated significantly with all of the most relevant clinical and biological parameters. Multivariate analysis selected only high reactive C protein (P = 0.0005), bone marrow infiltration (P = 0.02) and bone pain (P = 0.002) as factors affecting 99mTc-MIBI pattern. In 22 patients with solitary myeloma, 99mTc-MIBI was positive in 86% of cases and detected more disease sites than X-ray. Among 168 scans performed during follow-up, 99mTc-MIBI presented high specificity in patients showing a complete response (CR; 86%), and correlated with myeloma activity and with response to therapy. At multivariate analysis, a positive pattern correlated with bone marrow infiltration (P = 0.002) and disease status other than CR (P = 0.03). We conclude that 99mTc-MIBI scanning is an additional diagnostic tool with a high specificity for the staging and the follow-up of multiple myeloma patients.lld:pubmed
pubmed-article:17233770pubmed:languageenglld:pubmed
pubmed-article:17233770pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17233770pubmed:citationSubsetIMlld:pubmed
pubmed-article:17233770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17233770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17233770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17233770pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17233770pubmed:statusMEDLINElld:pubmed
pubmed-article:17233770pubmed:monthMarlld:pubmed
pubmed-article:17233770pubmed:issn0007-1048lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:VisaniGiusepp...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:IsidoriAlessa...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:LeoniPietroPlld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:OffidaniMassi...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:CorvattaLaura...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:BrunoriMarino...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:MeleAnnaAlld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:MarconiMonica...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:CatariniMassi...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:AgostiniVanes...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:BrianzoniErne...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:BerbelliniAlf...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:CambioliFilip...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:NonniMarcoMlld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:AscoliGiorgio...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:SpinelliAurel...lld:pubmed
pubmed-article:17233770pubmed:authorpubmed-author:GradariMarine...lld:pubmed
pubmed-article:17233770pubmed:issnTypePrintlld:pubmed
pubmed-article:17233770pubmed:volume136lld:pubmed
pubmed-article:17233770pubmed:ownerNLMlld:pubmed
pubmed-article:17233770pubmed:authorsCompleteYlld:pubmed
pubmed-article:17233770pubmed:pagination729-35lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:meshHeadingpubmed-meshheading:17233770...lld:pubmed
pubmed-article:17233770pubmed:year2007lld:pubmed
pubmed-article:17233770pubmed:articleTitleTechnetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.lld:pubmed
pubmed-article:17233770pubmed:affiliationDepartment of Haematology, San Salvatore Hospital, Pesaro, Italy.lld:pubmed
pubmed-article:17233770pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17233770pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:17233770pubmed:publicationTypeEvaluation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17233770lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17233770lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17233770lld:pubmed